Literature DB >> 16828425

Clinical results of surgery for retroperitoneal sarcoma with major blood vessel involvement.

Matthias H M Schwarzbach1, Yura Hormann, Ulf Hinz, Christine Leowardi, Dittmar Böckler, Gunhild Mechtersheimer, Helmut Friess, Markus W Büchler, Jens-R Allenberg.   

Abstract

PURPOSE: The study was conducted to evaluate the clinical results of resection for retroperitoneal soft tissue sarcoma (STS) with vascular involvement.
METHODS: The study group consisted of consecutive patients (mean age, 52 years) who underwent surgery for retroperitoneal STS with vascular involvement. The procedures were performed between 1988 and 2004. Vessel involvement by STS was classified as type I, artery and vein; type II, only artery; type III, only vein; and type IV, neither artery nor vein (excluded from the analysis). Patient data were prospectively gathered in a computerized database and retrospectively analyzed.
RESULTS: Of 141 patients with retroperitoneal STS, 25 (17.7%) underwent surgery for tumors with vascular involvement. The most common vascular involvement pattern was vein only (type III) at 64%. Arterial and vein (type I) and arterial only (type II) involvement were observed in 16% and 20% of the cases, respectively. STS originating from the vessel wall (primary vessel involvement) was seen in eight patients, and 17 patients had secondary vascular involvement. Resection and vascular repair were done in 22 patients (no vascular repair in three patients due to ligation of the external iliac vein in one patient, and debulking procedures in two). All patients with arterial involvement (type I and II) had arterial reconstruction consisting of aortic replacement (Dacron, n = 3; and expanded polytetrafluoroethylene [ePTFE], n = 2), iliac repair (Dacron, n = 3), and truncal reimplantation (n = 1). The inferior vena cava (6 ePTFE tube grafts, 3 ePTFE patches, 2 venoplasties), iliac vein (1 ePTFE bypass, 1 Dacron bypass, 1 venous patch), and superior mesenteric vein (1 anastomosis, 1 Dacron bypass) were restored in 80% of the patients (n = 16) with either arterial and venous or only venous involvement (type I and type III setting). Morbidity was 36% (hemorrhage, others), and mortality was 4%. At a median follow-up of 19.3 months (interquartile range, 12.8 to 49.9 months) the arterial patency rate was 88.9%, and the venous patency rate was 93.8% (primary and secondary). Thrombosis developed in one arterial and venous (type I) iliac reconstruction due to a perforated sigmoid diverticulitis 12 months after surgery. The local control rate was 82.4%. The 2-year and 5-year survival rates were 90% and 66.7% after complete resection with tumor-free resection margins (n = 10 patients, median survival not reached at latest follow-up). The median survival was 21 months in patients with complete resection but positive resection margins (n = 7) and 8 months in patients with incomplete tumor clearance (n = 8, persistent local disease or metastasis).
CONCLUSIONS: Patency rates and an acceptable surgical risk underline the value of en bloc resection of retroperitoneal STS together with involvement of blood vessels. The oncologic outcome is positive, especially after complete resection with tumor-free resection margins. A classification of vascular involvement can be used to plan resection and vascular replacement as well as to compare results among reports in a standardized fashion.

Entities:  

Mesh:

Year:  2006        PMID: 16828425     DOI: 10.1016/j.jvs.2006.03.001

Source DB:  PubMed          Journal:  J Vasc Surg        ISSN: 0741-5214            Impact factor:   4.268


  32 in total

1.  Long-term results of primary and secondary resections in patients with retroperitoneal soft tissue sarcoma.

Authors:  Alexandra M Koenig; Matthias Reeh; Christoph M Burdelski; Claudia Wengert; Karim A Gawad; Jakob R Izbicki; Maximilian Bockhorn
Journal:  Langenbecks Arch Surg       Date:  2012-03-10       Impact factor: 3.445

Review 2.  [Vascular replacement in abdominal tumor surgery].

Authors:  A Mehrabi; P Houben; N Attigah; D Böckler; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2011-10       Impact factor: 0.955

3.  Retroperitoneal sarcomas- a challenging problem.

Authors:  Vijay Kumar; Sanjeev Misra; Arun Chaturvedi
Journal:  Indian J Surg Oncol       Date:  2012-05-30

4.  Ex vivo excision of retroperitoneal soft tissue tumors: A case report.

Authors:  Amir A Rahnemai-Azar; Adam D Griesemer; Monica L Velasco; Tomoaki Kato
Journal:  Oncol Lett       Date:  2017-08-23       Impact factor: 2.967

5.  The Use of Autologous Peritoneum for Complete Caval Replacement Following Resection of Major Intra-abdominal Malignancies.

Authors:  Laurent Coubeau; Juan-Manuel Rico Juri; Olga Ciccarelli; Nicolas Jabbour; Jan Lerut
Journal:  World J Surg       Date:  2017-04       Impact factor: 3.352

6.  Resection of retroperitoneal sarcoma en-bloc with inferior vena cava: 20 year outcomes of a single institution.

Authors:  Alex B Blair; Bradley N Reames; Jasvinder Singh; Faiz Gani; Heidi N Overton; Robert J Beaulieu; Ying W Lum; James H Black; Fabian M Johnston; Nita Ahuja
Journal:  J Surg Oncol       Date:  2018-06-07       Impact factor: 3.454

7.  A confusing case: pulmonary lesions including cavities, isolated left heart endocarditis and inferior vena cava thrombosis in a patient with perforated diverticulitis.

Authors:  Metin Işik; Esat Çinar; M Cemal Kizilarslanoğlu; Emre Özbek; Sezgin Etgül; Sedat Kiraz
Journal:  Rheumatol Int       Date:  2012-03-28       Impact factor: 2.631

Review 8.  Giant retroperitoneal liposarcoma with mixed histological pattern: a rare presentation and literature review.

Authors:  Nikolaos S Salemis; Evangelos Tsiambas; Andreas Karameris; Efstathios Tsohataridis
Journal:  J Gastrointest Cancer       Date:  2009

Review 9.  [Surgical therapy of abdominal and trunk soft tissue sarcomas].

Authors:  S Schimmack; M W Büchler; J Weitz
Journal:  Chirurg       Date:  2009-03       Impact factor: 0.955

10.  Sarcoma Resection With and Without Vascular Reconstruction: A Matched Case-control Study.

Authors:  George A Poultsides; Thuy B Tran; Eduardo Zambrano; Lucas Janson; David G Mohler; Matthew W Mell; Raffi S Avedian; Brendan C Visser; Jason T Lee; Kristen Ganjoo; E John Harris; Jeffrey A Norton
Journal:  Ann Surg       Date:  2015-10       Impact factor: 12.969

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.